Skip to main content
Top
Published in: Infection 3/2010

01-06-2010 | Clinical and Epidemiological Study

Methicillin-resistant Staphylococcus aureus (MRSA) in Europe: which infection control measures are taken?

Authors: S. Hansen, F. Schwab, A. Asensio, H. Carsauw, P. Heczko, I. Klavs, O. Lyytikäinen, M. Palomar, I. Riesenfeld-Orn, A. Savey, E. Szilagyi, R. Valinteliene, J. Fabry, P. Gastmeier

Published in: Infection | Issue 3/2010

Login to get access

Abstract

Background

The prevalence of hospital-acquired Methicillin-resistant Staphylococcus aureus (MRSA) infections shows a huge variety across Europe. Some countries reported a reduction in MRSA frequency, while in others countries increasing MRSA rates have been observed. To reduce the spread of MRSA in the healthcare setting, a sufficient MRSA management is essential. In order to reflect the MRSA management across Europe, MRSA prevention policies were surveyed in ten countries.

Materials and methods

The survey was performed by questionnaires in European intensive care units (ICUs) and surgical departments (SDs) in 2004. Questionnaires asked for availability of bedside alcohol hand-disinfection, isolation precautions, decolonization and screening methods. The study was embedded in the Hospital in Europe Link for Infection Control through Surveillance (HELICS) Project, a European collaboration of national surveillance networks. HELICS was initiated in order to harmonize the national surveillance activities in the individual countries. Therefore, HELICS participants developed surveillance modules for nosocomial infections in ICUs and for surgical site infections (SSI). The coordination of this surveillance has now been transferred to the European Centre for Disease Prevention and Control (ECDC).

Results

A total of 526 ICUs and 223 SDs from ten countries sent data on organisational characteristics and policies, demonstrating wide variations in care. Substantial variation existed in availability of bedside alcohol hand-disinfection, which was much higher in participating ICUs rather than in SDs (86 vs. 59%). Surveillance cultures of contact patients were obtained in approximately three-fourths of all SDs (72%) and ICUs (75%). Countries with decreasing MRSA proportions showed especially strict implementation of various prevention measures.

Conclusion

The data obtained regarding MRSA prevention measures should stimulate infection control professionals to pursue further initiatives. Particularly, the vigorous MRSA management in countries with decreasing MRSA proportions should encourage hospitals to implement preventive measures in order to reduce the spread of MRSA.
Literature
1.
go back to reference Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53–9.CrossRefPubMed Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53–9.CrossRefPubMed
2.
go back to reference Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:592–8.CrossRefPubMed Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:592–8.CrossRefPubMed
3.
go back to reference Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust. 2001;175:264–7.PubMed Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust. 2001;175:264–7.PubMed
4.
go back to reference Tiemersma EW, Bronzwaer SL, Lyytikainen O, et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis. 2004;10:1627–34.PubMed Tiemersma EW, Bronzwaer SL, Lyytikainen O, et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis. 2004;10:1627–34.PubMed
5.
go back to reference Anonymous. Recent trends in antimicrobial resistance among Streptococcus pneumoniae and Staphylococcus aureus isolates: the French experience. Euro Surveill 2008;13(46). pii:19035 Anonymous. Recent trends in antimicrobial resistance among Streptococcus pneumoniae and Staphylococcus aureus isolates: the French experience. Euro Surveill 2008;13(46). pii:19035
6.
go back to reference Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003;24:362–86.CrossRefPubMed Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003;24:362–86.CrossRefPubMed
7.
go back to reference Coia JE, Duckworth GJ, Edwards DI, et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect. 2006;63(Suppl 1):S1–44.CrossRefPubMed Coia JE, Duckworth GJ, Edwards DI, et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect. 2006;63(Suppl 1):S1–44.CrossRefPubMed
8.
go back to reference Suetens C, Morales I, Savey A, et al. European surveillance of ICU-acquired infections (HELICS-ICU): methods and main results. J Hosp Infect. 2007;65(Suppl 2):171–3.CrossRefPubMed Suetens C, Morales I, Savey A, et al. European surveillance of ICU-acquired infections (HELICS-ICU): methods and main results. J Hosp Infect. 2007;65(Suppl 2):171–3.CrossRefPubMed
9.
go back to reference Wilson J, Ramboer I, Suetens C. Hospitals in Europe Link for Infection Control through Surveillance (HELICS). Inter-country comparison of rates of surgical site infection––opportunities and limitations. J Hosp Infect. 2007;65(Suppl 2):165–70.CrossRefPubMed Wilson J, Ramboer I, Suetens C. Hospitals in Europe Link for Infection Control through Surveillance (HELICS). Inter-country comparison of rates of surgical site infection––opportunities and limitations. J Hosp Infect. 2007;65(Suppl 2):165–70.CrossRefPubMed
10.
go back to reference Hansen S, Schwab F, Behnke M, et al. National influences on catheter-associated bloodstream infection rates: practices among national surveillance networks participating in the European HELICS project. J Hosp Infect. 2009;71:66–73.CrossRefPubMed Hansen S, Schwab F, Behnke M, et al. National influences on catheter-associated bloodstream infection rates: practices among national surveillance networks participating in the European HELICS project. J Hosp Infect. 2009;71:66–73.CrossRefPubMed
11.
go back to reference Moro ML, Jepsen OB. Infection control practices in intensive care units of 14 European countries. The EURO.NIS Study Group. Intensive Care Med. 1996;22:872–9.CrossRefPubMed Moro ML, Jepsen OB. Infection control practices in intensive care units of 14 European countries. The EURO.NIS Study Group. Intensive Care Med. 1996;22:872–9.CrossRefPubMed
12.
go back to reference Struelens MJ, Wagner D, Bruce J, et al. Status of infection control policies and organisation in European hospitals, 2001: the ARPAC study. Clin Microbiol Infect. 2006;12:729–37.CrossRefPubMed Struelens MJ, Wagner D, Bruce J, et al. Status of infection control policies and organisation in European hospitals, 2001: the ARPAC study. Clin Microbiol Infect. 2006;12:729–37.CrossRefPubMed
13.
go back to reference MacKenzie FM, Bruce J, Struelens MJ, Goossens H, Mollison J, Gould IM. Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals. Clin Microbiol Infect. 2007;13:269–76.CrossRefPubMed MacKenzie FM, Bruce J, Struelens MJ, Goossens H, Mollison J, Gould IM. Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals. Clin Microbiol Infect. 2007;13:269–76.CrossRefPubMed
14.
go back to reference Bootsma MC, Diekmann O, Bonten MJ. Controlling methicillin-resistant Staphylococcus aureus: quantifying the effects of interventions and rapid diagnostic testing. Proc Natl Acad Sci USA. 2006;103:5620–5.CrossRefPubMed Bootsma MC, Diekmann O, Bonten MJ. Controlling methicillin-resistant Staphylococcus aureus: quantifying the effects of interventions and rapid diagnostic testing. Proc Natl Acad Sci USA. 2006;103:5620–5.CrossRefPubMed
15.
go back to reference Tomic V, Svetina SP, Trinkaus D, Sorli J, Widmer AF, Trampuz A. Comprehensive strategy to prevent nosocomial spread of methicillin-resistant Staphylococcus aureus in a highly endemic setting. Arch Intern Med. 2004;164:2038–43.CrossRefPubMed Tomic V, Svetina SP, Trinkaus D, Sorli J, Widmer AF, Trampuz A. Comprehensive strategy to prevent nosocomial spread of methicillin-resistant Staphylococcus aureus in a highly endemic setting. Arch Intern Med. 2004;164:2038–43.CrossRefPubMed
Metadata
Title
Methicillin-resistant Staphylococcus aureus (MRSA) in Europe: which infection control measures are taken?
Authors
S. Hansen
F. Schwab
A. Asensio
H. Carsauw
P. Heczko
I. Klavs
O. Lyytikäinen
M. Palomar
I. Riesenfeld-Orn
A. Savey
E. Szilagyi
R. Valinteliene
J. Fabry
P. Gastmeier
Publication date
01-06-2010
Publisher
Urban and Vogel
Published in
Infection / Issue 3/2010
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-010-0001-8

Other articles of this Issue 3/2010

Infection 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine